Horm Metab Res 2015; 47(13): 933-934
DOI: 10.1055/s-0035-1565125
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Progress in Primary Aldosteronism: Translation on the Move

M. Reincke
1  Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
,
F. Beuschlein
1  Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
› Author Affiliations
Further Information

Publication History

received 14 October 2015

accepted 15 October 2015

Publication Date:
14 December 2015 (online)

Hypertension is a major cardiovascular risk factor that affects between 10–40% of the general population in an age dependent manner. The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure, fluid volume, and the vascular response to injury and inflammation [1]. Chronic RAAS activation in the presence of sufficient sodium consumption leads to persistent hypertension, setting off a cascade of inflammatory, thrombotic, and atherogenic effects eventually leading to end-organ damage [2] [3]. Accordingly, numerous studies have demonstrated that elevated renin and/or aldosterone levels are predictors of adverse outcome in hypertension [4], heart failure [5] [6], myocardial infarction [7], and renal insufficiency [8] and influence insulin resistance [9]. Primary aldosteronism (PA) is the most common secondary form of hypertension with an estimated prevalence between 4 and 12% of hypertensives [10] [11] [12] and 11–20% in patients that are resistant to combined antihypertensive medication [13] [14]. Given the severe cardiovascular adverse effects of aldosterone excess that are independent of high blood pressure levels [15] [16] [17] [18] detection and treatment of PA has important impact on clinical outcome and survival.